Can a lower dose of acetazolamide prevent acute mountain sickness?

The RADICAL Trial was a prospective, double-blind, randomized, non-inferiority trial evaluating reduced dose (62.5 mg twice daily) vs. standard dose (125 mg twice daily) of acetazolamide for the prevention of acute mountain sickness in adults trekking to Everest Base Camp in Nepal.(1). Background: The current standard pharmacologic prophylaxis for acute Read more…